항우울제 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Antidepressant Drugs Market was valued at USD 19.8 billion in 2025 and is estimated to grow at a CAGR of 7.7% to reach USD 41.2 billion by 2035.

The market is witnessing substantial growth due to the increasing incidence of depression, anxiety-related disorders, and other psychiatric conditions worldwide. Rising awareness regarding mental health treatment and growing acceptance of pharmacological therapies are significantly supporting industry expansion. Continuous advancements in pharmaceutical research are also contributing to the introduction of more effective antidepressant therapies designed to improve long-term patient outcomes. The growing focus on managing treatment-resistant mental health conditions is encouraging the development of innovative therapeutic solutions with improved clinical performance. In addition, broader availability of affordable generic antidepressants is increasing treatment accessibility across emerging and developing economies. The expansion of telehealth services and digital healthcare platforms is further improving access to psychiatric care among underserved populations. Antidepressant medications are widely utilized for the treatment of multiple mental health disorders and continue to play a critical role in supporting emotional wellbeing and long-term psychiatric disease management across global healthcare systems.

The antidepressant drugs market continues to benefit from increasing healthcare investments and expanding mental health support infrastructure worldwide. Growing awareness campaigns and public health initiatives focused on reducing the stigma associated with mental illness are encouraging more individuals to seek professional treatment and medication-based therapy solutions. The rising burden of emotional stress, lifestyle-related psychological disorders, and chronic mental health conditions is further strengthening demand for antidepressant therapies. Pharmaceutical companies are increasingly focusing on the development of advanced formulations with improved safety, tolerability, and faster therapeutic response rates, supporting continued market growth throughout the forecast period.

The Selective Serotonin Reuptake Inhibitors (SSRIs) segment accounted for a share of 55.7% in 2025. The strong market position of SSRIs is primarily supported by their proven therapeutic effectiveness, favorable safety profile, and improved patient tolerability compared to conventional antidepressant drug classes. These therapies are widely preferred as first-line treatment options for depression and anxiety-related conditions due to their lower risk of adverse effects and broader suitability across diverse patient populations. Increasing physician preference for safer and more effective treatment approaches is further contributing to segment growth worldwide.

The oral segment is projected to reach USD 32.8 billion by 2035. Segment growth is mainly driven by strong patient preference for oral dosage forms due to their convenience, affordability, ease of administration, and non-invasive nature. The widespread availability of both branded and generic oral antidepressant medications has also improved accessibility across various healthcare settings and patient demographics. In addition, oral antidepressants continue to maintain high adoption rates due to their established long-term efficacy and favorable safety records in the treatment of psychiatric disorders.

North America Antidepressant Drugs Market accounted for 39.9% share in 2025. The region continues to lead the market due to the high prevalence of mental health disorders, strong healthcare spending, and broad adoption of advanced psychiatric treatment solutions. Well-developed healthcare infrastructure, favorable reimbursement policies, and growing awareness regarding mental health management are contributing significantly to market expansion across North America. Rising diagnosis rates and increasing access to specialized psychiatric care services are further strengthening the region's market position throughout the forecast period.

Major companies operating in the Antidepressant Drugs Market include Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, N.V. Organon, Novartis, Opko Health, Otsuka Pharmaceutical, Patheon, Pfizer, Sandoz, Sun Pharmaceuticals, Taj Pharma, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, and Zhejiang NHU Company. Companies operating in the Antidepressant Drugs Market are implementing several strategic initiatives to strengthen their market presence and improve competitive positioning globally. Leading pharmaceutical companies are investing heavily in research and development activities to introduce innovative antidepressant therapies with enhanced efficacy, improved safety profiles, and faster therapeutic outcomes. Strategic collaborations, licensing agreements, and mergers are helping organizations expand product portfolios and accelerate drug commercialization across international markets. Companies are also focusing on increasing generic drug production to improve affordability and broaden patient access to antidepressant medications. Expanding digital healthcare integration, telemedicine partnerships, and online pharmacy distribution channels are further supporting market penetration. In addition, industry participants are prioritizing regulatory approvals, advanced formulation technologies, and awareness initiatives to strengthen brand visibility and reinforce their foothold within the global antidepressant drugs industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Application trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Medication type trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of depression and anxiety disorders
    • 3.2.1.2 Increasing investment in research and development
    • 3.2.1.3 Growing awareness regarding treatment therapies and mental health
    • 3.2.1.4 Advancements in personalized medicine
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with some antidepressant drugs
    • 3.2.2.2 Customer preference for non-pharmacological therapeutics over pharmacological therapeutics
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing adoption of telepsychiatry and digital health platforms
    • 3.2.3.2 Increasing focus on pediatric and adolescent mental health
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Pipeline analysis (Driven by Primary Research)
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Impact of AI and generative AI on the market (Driven by Primary Research)
• 3.8 Consumer behaviour analysis (Driven by Primary Research)
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Selective serotonin reuptake inhibitors (SSRIs)
• 5.3 Serotonin and noradrenaline reuptake inhibitors (SNRIs)
• 5.4 Tricyclic antidepressants (TCAs)
• 5.5 Atypical antidepressants
• 5.6 Norepinephrine-dopamine reuptake inhibitor (NDRI)
• 5.7 Monoamine oxidase inhibitors (MAOIs)
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Major depressive disorder
• 6.3 Generalized anxiety disorder
• 6.4 Obsessive-compulsive disorder
• 6.5 Panic disorder
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Nasal
• 7.5 Transdermal

Chapter 8 Market Estimates and Forecast, By Medication Type, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Branded
• 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bristol-Myers Squibb
• 11.2 Eli Lilly and Company
• 11.3 GlaxoSmithKline
• 11.4 H. Lundbeck
• 11.5 Johnson & Johnson
• 11.6 N.V. Organon
• 11.7 Novartis
• 11.8 Opko Health
• 11.9 Otsuka Pharmaceutical
• 11.10 Patheon
• 11.11 Pfizer
• 11.12 Sandoz
• 11.13 Sun Pharmaceuticals
• 11.14 Taj Pharma
• 11.15 Takeda Pharmaceuticals
• 11.16 Teva Pharmaceutical Industries
• 11.17 Zhejiang NHU Company